## Hideyuki Arita

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2934550/publications.pdf

Version: 2024-02-01

53	1,968	23	43
papers	citations	h-index	g-index
53	53	53	3201 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Prognostic significance of TERT promoter mutations in adult-type diffuse gliomas. Brain Tumor Pathology, 2022, 39, 121-129.	1.7	7
2	Fine-Tuning Approach for Segmentation of Gliomas in Brain Magnetic Resonance Images with a Machine Learning Method to Normalize Image Differences among Facilities. Cancers, 2021, 13, 1415.	3.7	28
3	Clinical significance of <i>CDKN2A</i> homozygous deletion in combination with methylated <i>MGMT</i> status for <i>IDH</i> â€wildtype glioblastoma. Cancer Medicine, 2021, 10, 3177-3187.	2.8	21
4	TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Acta Neuropathologica, 2021, 142, 323-338.	7.7	58
5	Eribulin prolongs survival in an orthotopic xenograft mouse model of malignant meningioma. Cancer Science, 2021, 113, 697.	3.9	4
6	TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations. Acta Neuropathologica Communications, 2020, 8, 201.	5.2	27
7	Molecular characteristics and clinical outcomes of elderly patients with IDH-wildtype glioblastomas: comparative study of older and younger cases in Kansai Network cohort. Brain Tumor Pathology, 2020, 37, 50-59.	1.7	14
8	Primary central nervous system lymphoma of the bilateral Bochdalek's flower baskets: A case report. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 2020, 21, 100756.	0.3	0
9	Impact of Inversion Time for FLAIR Acquisition on the T2-FLAIR Mismatch Detectability for IDH-Mutant, Non-CODEL Astrocytomas. Frontiers in Oncology, 2020, 10, 596448.	2.8	14
10	A Sufficient Surgical Window for Deep-Seated Extracranial Schwannomas in the Craniocervical Junction by the Anterolateral Approach. Neurospine, 2020, 17, 453-460.	2.9	0
11	Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma. Scientific Reports, 2019, 9, 14435.	3.3	58
12	Validation of magnetic resonance imaging‑based automatic high‑grade glioma segmentation accuracy via 11C‑methionine positron emission tomography. Oncology Letters, 2019, 18, 4074-4081.	1.8	1
13	Distribution differences in prognostic copy number alteration profiles in IDH-wild-type glioblastoma cause survival discrepancies across cohorts. Acta Neuropathologica Communications, 2019, 7, 99.	5.2	32
14	Clinical Characteristics of Acromegalic Patients With Paradoxical GH Response to Oral Glucose Load. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1637-1644.	3.6	11
15	Prediction of IDH and TERT promoter mutations in low-grade glioma from magnetic resonance images using a convolutional neural network. Scientific Reports, 2019, 9, 20311.	3.3	45
16	11C-methionine-18F-FDG dual-PET-tracer–based target delineation of malignant glioma: evaluation of its geometrical and clinical features for planning radiation therapy. Journal of Neurosurgery, 2019, 131, 676-686.	1.6	15
17	Voxel-based lesion mapping of meningioma: a comprehensive lesion location mapping of 260 lesions. Journal of Neurosurgery, 2018, 128, 1707-1712.	1.6	9
18	Enchondromatosis-associated oligodendroglioma: case report and literature review. Brain Tumor Pathology, 2018, 35, 36-40.	1.7	8

#	Article	IF	CITATIONS
19	LPA4-Mediated Vascular Network Formation Increases the Efficacy of Anti–PD-1 Therapy against Brain Tumors. Cancer Research, 2018, 78, 6607-6620.	0.9	28
20	Characteristics and outcomes of elderly patients with diffuse gliomas: a multi-institutional cohort study by Kansai Molecular Diagnosis Network for CNS Tumors. Journal of Neuro-Oncology, 2018, 140, 329-339.	2.9	25
21	A case report of granulomatous amoebic encephalitis by Group 1 Acanthamoeba genotype T18 diagnosed by the combination of morphological examination and genetic analysis. Diagnostic Pathology, 2018, 13, 27.	2.0	13
22	Influence of regionâ€ʻofâ€ʻinterest designs on quantitative measurement of multimodal imaging of MR nonâ€ʻenhancing gliomas. Oncology Letters, 2018, 15, 7934-7940.	1.8	3
23	Lesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade II/III gliomas. Scientific Reports, 2018, 8, 11773.	3.3	88
24	Diagnostic and Prognostic Value of $\sup 11$ / $\sup C$ -Methionine PET for Nonenhancing Gliomas. American Journal of Neuroradiology, 2016, 37, 44-50.	2.4	37
25	A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathologica Communications, 2016, 4, 79.	5.2	189
26	Recurrent mutations of <scp><i>CD79B</i></scp> and <scp><i>MYD88</i></scp> are the hallmark of primary central nervous system lymphomas. Neuropathology and Applied Neurobiology, 2016, 42, 279-290.	3.2	172
27	Comparison of diffusion tensor imaging and 11C-methionine positron emission tomography for reliable prediction of tumor cell density in gliomas. Journal of Neurosurgery, 2016, 125, 1136-1142.	1.6	16
28	Glioblastomas with <i>IDH1/2</i> mutations have a short clinical history and have a favorable clinical outcome. Japanese Journal of Clinical Oncology, 2016, 46, 31-39.	1.3	15
29	Introduction of High Throughput Magnetic Resonance T2-Weighted Image Texture Analysis for WHO Grade 2 and 3 Gliomas. PLoS ONE, 2016, 11, e0164268.	2.5	36
30	Human chorionic gonadotropin is expressed virtually in all intracranial germ cell tumors. Journal of Neuro-Oncology, 2015, 124, 23-32.	2.9	26
31	Multinodular and vacuolating neuronal tumor of the cerebrum. Brain Tumor Pathology, 2015, 32, 131-136.	1.7	42
32	Pituitary-Targeted Dynamic Contrast-Enhanced Multisection CT for Detecting MR Imaging–Occult Functional Pituitary Microadenoma. American Journal of Neuroradiology, 2015, 36, 904-908.	2.4	25
33	IDH1/2 mutation detection in gliomas. Brain Tumor Pathology, 2015, 32, 79-89.	1.7	44
34	Revisiting <scp><i>TP</i></scp> <i>53</i> <mutations 157="" 2015,="" 25,="" 256-265.<="" and="" brain="" comparative="" diffuse="" gliomas.="" immunohistochemistryâ€"a="" in="" pathology,="" study="" td=""><td>4.1</td><td>120</td></mutations>	4.1	120
35	Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas. Brain Tumor Pathology, 2015, 32, 22-30.	1.7	65
36	Different spatial distribution between germinal center B and non-germinal center B primary central nervous system lymphoma revealed by magnetic resonance group analysis. Neuro-Oncology, 2014, 16, 728-734.	1.2	18

#	Article	lF	Citations
37	<i>Gsp</i> mutation in acromegaly and its influence on <scp>TRH</scp> â€induced paradoxical <scp>GH</scp> response. Clinical Endocrinology, 2014, 80, 714-719.	2.4	2
38	Usefulness of a glass-free medical three-dimensional autostereoscopic display in neurosurgery. International Journal of Computer Assisted Radiology and Surgery, 2014, 9, 905-911.	2.8	20
39	Short communication: sclerosing meningioma in the deep sylvian fissure. Brain Tumor Pathology, 2014, 31, 289-292.	1.7	14
40	Risk factors for early death after surgery in patients with brain metastases: reevaluation of the indications for and role of surgery. Journal of Neuro-Oncology, 2014, 116, 145-152.	2.9	26
41	Prevalence of cerebral aneurysm in patients with acromegaly. Pituitary, 2013, 16, 195-201.	2.9	34
42	TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas. Acta Neuropathologica, 2013, 126, 939-941.	7.7	62
43	Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathologica, 2013, 126, 267-276.	7.7	315
44	Management of glioblastoma in an NF1 patient with moyamoya syndrome: a case report. Child's Nervous System, 2013, 29, 341-345.	1.1	7
45	Extended trastuzumab therapy improves the survival of HER2-positive breast cancer patients following surgery and radiotherapy for brain metastases. Molecular and Clinical Oncology, 2013, 1, 995-1001.	1.0	10
46	Biological Characteristics of Growth Hormone-Producing Pituitary Adenomas Are Different According to Responsiveness to Thyrotropin-Releasing Hormone. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2741-2747.	3.6	8
47	Hemifacial spasm caused by intra-axial brainstem cavernous angioma with venous angiomas. British Journal of Neurosurgery, 2012, 26, 281-283.	0.8	11
48	A Novel PET Index, <sup>18</sup> F-FDG– <sup>11</sup> C-Methionine Uptake Decoupling Score, Reflects Glioma Cell Infiltration. Journal of Nuclear Medicine, 2012, 53, 1701-1708.	5.0	38
49	<sup>11</sup> Câ€methionine uptake and intraoperative 5â€aminolevulinic acidâ€induced fluorescence as separate index markers of cell density in glioma. Cancer, 2012, 118, 1619-1627.	4.1	38
50	Imaging 18F-fluorodeoxy glucose/ $11C$ -methionine uptake decoupling for identification of tumor cell infiltration in peritumoral brain edema. Journal of Neuro-Oncology, 2012, 106, 417-425.	2.9	22
51	Clinical characteristics of meningiomas assessed by 11C-methionine and 18F-fluorodeoxyglucose positron-emission tomography. Journal of Neuro-Oncology, 2012, 107, 379-386.	2.9	39
52	Posttransplant Lymphoproliferative Disorders of the Central Nervous System After Kidney Transplantation: Single Center Experience Over 40 Years -Two Case Reports Neurologia Medico-Chirurgica, 2010, 50, 1079-1083.	2.2	8
53	Revisiting the definition of glioma recurrence based on a phylogenetic investigation of primary and re-emerging tumor samples: a case report. Brain Tumor Pathology, 0, , .	1.7	0